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Menghi and co-workers report a metric to classify tumours into those with and 
without a tandem duplicator phenotype (TDP) using the frequency of tandem 
duplications (TDs) in 277 whole genome sequenced samples (1). Building on 
a previous method (2), the authors identified TDs from SNP array data, and 
found that the TDP was strongly associated with response to  the DNA 
damaging chemotherapeutic, cisplatin. These findings supplement the 
growing recognition that genome-wide signatures of mutator phenotypes may 
prove to be important additions to the companion diagnostic repertoire (3, 4). 
Although the findings of this report are highly stimulating, accumulating 
evidence suggests that an elevated abundance of TDs features in not just one 
but two distinct phenotypes. 
 
Two of the original studies on the TDP reported a mutual exclusion with 
BRCA1/2 inactivation (2, 5), which conflicts with the enrichment of BRCA1 
loss among TDP cancers observed by Menghi and colleagues. Using TCGA 
breast cancer data (6), we established allele-specific copy number profiles 
using ASCAT (7) before calling TDP status as described previously (2) using 
two different size ranges for the TD-like features: (i) between 1Kbp and 2Mbp 
in accordance with the study by Menghi and associates; and (ii) between 
2Mbp and 10Mbp. Five samples with BRCA1 inactivation exhibited the TDP 
when considering only shorter TDs (Fig. 1A); however, we found no instances 
of tumours with BRCA1 inactivation among 2–10Mbp TDP cancers (Fig. 1B). 
Furthermore, while 56% of the Menghi et al study’s TDP calls were shared 
with our 1Kbp–2Mbp TDP calls, only 10% of the Menghi et al study’s TDP 
calls agreed with our 2–10Mbp TDP calls (Fig. 1C). In addition, we found that 
while the 1Kbp–2Mbp TDP calls and the Menghi et al study’s TDP calls were 
enriched for triple-negative breast cancers (P<0.001, Fisher’s exact test), the 
2Mbp–10 Mbp TDP calls were not (P=0.81, Fisher’s exact test). These 
findings support the notion that the study by Menghi and associates captures 
one particular TDP distinguishable from a second TDP by length and 
contrasting relationships with loss of BRCA1 function.  
 
Our results are reinforced by two recent analyses. The first study extracted 
two TD-enriched rearrangement signatures from 560 whole breast cancer 
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genomes (8). ‘Signature-1’ mostly comprised TDs between 1 and 10Mbp, 
whereas ‘signature-3’ mostly comprised TDs ≤100Kbp. Signature-3 was 
associated with BRCA1 disruption, signatures of homologous recombination 
deficiency (HRD), and was observed in ~15% of the cohort. By contrast, 
signature-1 was independent of BRCA1/2 disruptions, exhibited links with 
mutational signatures of both HRD and mismatch repair deficiency, and 
presented in ~8.5% of the cohort. The second study identified an ovarian and 
prostate cancer-linked TDP featuring TDs up to 10Mbp, mutual exclusion with 
BRCA1/2 inactivation and enrichment for inactivation of the CDK12 kinase (9). 
 
In conclusion, we propose that there are actually two TDPs, with the study by 
Menghi and colleagues providing a comprehensive characterisation of the 
BRCA1 inactivation-linked TDP. The existence of two TDPs has important 
implications for the robust development of genomic instability-based 
biomarkers of drug response.  
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Figure legend 
Fig. 1. Tandem duplication phenotypes in 940 TCGA breast cancers. (A 
and B) TDP status was determined using genomic segments between 1 Kbp 
and 2 Mbp (A), or 2 Mbp and 10 Mbp (B) followed by Gaussian mixture 
modelling of the ratio of TDs to non-TD segments (total number of segments 
minus double the number of TD segments as per (2)). Odds ratio and p-value 
represent Fisher’s exact test of BRCA1 mutation enrichment in the TDP 
subset of tumours. BRCA1 loss was defined as germline or somatic point 
mutation, or deletion. TDP tumours are coloured in red and non-TDP tumours 
in grey. All samples are denoted by a cross with the exception of tumours with 
BRCA1 loss, which are denoted by a square. (C) Bar plots illustrate the 
overlaps between the different TDP calling methods.  
QRQïWDQGHPUHSHDWïOLkHVHJPHQWV

WD
QG
HP
U
HS
HD
Wï
OLk
H
fH
DW
XU
HV
0 200 300 400 500 600 700
0
20
40
60
80
100
120
140
160
T D P
1RQïT D P
BRCA1 PXWDQW
& T D P
BRCA1 PXWDQW
& Non-T D P
A
Figure 1
100
OR = 3.495 
P = 0.02454

WD
QG
HP
U
HS
HD
Wï
OLk
H
fH
DW
XU
HV
0
20
40
50
QRQïWDQGHPUHSHDWïOLkHVHJPHQWV
0 200 300 400 500 600 700100
30
10
B
OR = 0 
P = 1
7HVWRIBRCA1HQULFKPHQW 7HVWRIBRCA1HQULFKPHQW
6L]HFRQVWUDLQWV.ES²0ES 6L]HFRQVWUDLQWV0ES²0ES
0.0
0.2
0.4
0.6
0.8
1.0
non-T
DP TDP
3
UR
SR
UW
LR
Q
RI
V
DP
SO
HV
non-T
DP TDPnon-T
DP TDP
0HQJKLet al.
.ES²0ES
0ES²0ES0HQJKLet al.
TDP
Non-TDP
0ES²0ES
TDP
Non-TDP
.ES²0ES
TDP
Non-TDP
C
